liver

Scientists found that the Kisspeptin hormone activates enzymes that stop lipid formation in the mouse liver, suggesting that it has potential as a drug target for treating non-alcoholic fatty liver disease.

Through academic, industry, and governmental partnerships, scientists validate and develop non-invasive diagnostics for non-alcoholic fatty liver disease. These tests are set to replace the invasive and risky gold standard: liver biopsy.